Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.46 |
| ▸ | MPO | P05164 | 2/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13469629 | 0.99 | MPO (0.45) | SIGMAR1MPOSLC2A1DRD2DRD4 | |
| SCHEMBL27961815 | 0.94 | SIGMAR1 (0.43) | SIGMAR1MPOSLC2A1S1PR1S1PR3 | |
| SCHEMBL17214332 | 0.90 | SLC2A1 (0.54) | SIGMAR1MPOSLC2A1DRD2DRD4 | |
| SCHEMBL13470134 | 0.88 | MMP2 (0.43) | SIGMAR1MPODRD2DRD4DRD3 | |
| SCHEMBL13469626 | 0.88 | MMP2 (0.43) | SIGMAR1MPODRD2DRD4DRD3 | |
| SCHEMBL13469699 | 0.88 | MMP2 (0.43) | SIGMAR1MPODRD2DRD4DRD3 | |
| SCHEMBL13469992 | 0.87 | CHRM2 (0.46) | SLC2A1 | |
| SCHEMBL13469664 | 0.86 | CYP1A2 (0.44) | SIGMAR1MPODRD2DRD4DRD3 | |
| SCHEMBL13469630 | 0.85 | KMT2A (0.46) | — | |
| SCHEMBL16024316 | 0.85 | SIGMAR1 (0.60) | SIGMAR1S1PR1S1PR3S1PR5S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658623-B2 | Substituted bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators | ALLERGAN, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8513418-B2 | Substituted bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators | ALLERGAN, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120264715-A1 | SUBSTITUTED BICYCLIC METHYL AMINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264715-A1 | SUBSTITUTED BICYCLIC METHYL AMINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | S1PR1, S1PR2, S1PR3 | SIGMAR1 115/4885MPO 4848/4885SLC2A1 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.